Anzeige
+++Wall Street. Trump. Antimon ATMY steht jetzt im Zentrum politischer Macht und kritischer Versorgung+++
Original-Research

Hoenle AG (von NuWays AG): BUY 02.02.2026, 09:00 Uhr von dpa-AFX Jetzt kommentieren: 0

Werte zum Artikel
Name Aktuell Diff. Börse
Dr.Hoenle 9,31 EUR +0,65 % Lang & Schwarz

^

Original-Research: Hoenle AG - from NuWays AG

02.02.2026 / 09:00 CET/CEST

Dissemination of a Research, transmitted by EQS News - a service of EQS

Group.

The issuer is solely responsible for the content of this research. The

result of this research does not constitute investment advice or an

invitation to conclude certain stock exchange transactions.

---------------------------------------------------------------------------

Classification of NuWays AG to Hoenle AG

Company Name: Hoenle AG

ISIN: DE0005157101

Reason for the research: Update

Recommendation: BUY

Target price: EUR 15

Target price on sight of: 12 months

Last rating change:

Analyst: Sarah Hellemann

FY 24/25 as expected // tide to turn in FY 25/26; chg.

Last week, Hoenle released its annual report for FY 24/25 (preliminary

figures were already published in Dec. 2025). Key takeaways in detail and

what to expect in FY 25/26:

FY 24/25 revenue declined by 5.1% yoy to EUR 93.7m (eNuW: EUR 93.7m) amidst a

challenging market environment, particularly for Adhesives and ongoing

restructuring in Curing, which were not compensated for by Disinfection. Q4

revenue stood at EUR 23.9m (-10.5% yoy). Importantly, FY 24/25 EBITDA

increased by 94% yoy to EUR 5.8m (eNuW: EUR 5.8m), thanks to positive

restructuring effects in Curing, a favourable product mix during the year

and general tight cost control. In Q4, EBITDA came in at EUR 2.7m (Q4 23/24:

-0.96m) implying a 11.4% margin.

Disinfection FY revenue rose by 6.7% to EUR 26.3m (eNuW: EUR 25.9m), as

tailwinds persisted and first revenues were recorded from the ultra-pure

water solutions. An EBITDA-contribution of EUR 3.2m (+ 6.6% yoy) supported the

overall result and rose largely in line with sales. Q4 revenue accelerated

by 10% yoy to EUR 7.2m with EUR 0.8m EBITDA (+93% yoy).

Adhesives FY revenue declined by 9.6% yoy to EUR 33.9m (eNuW: EUR 33.6m), due to

a notable reduction in automotive orders and shifting consumer electronic

supply chains amid high geopolitical uncertainty. The EBITDA amounted to EUR

2.8m (-36% yoy) accordingly. Q4 revenue fell by 7% yoy to EUR 9m, but EBITDA

contributed EUR 0.4m, compared to EUR -0.7m a year prior.

Curing FY revenue was down 8.5% yoy at EUR 33.4m (eNuW: EUR 34.2m), as a result

of lower end market demand and restructuring activities. These developments

led to a significantly lower EBITDA loss of EUR -0.2 m (vs EUR -3.2m in FY

23/24). While Q4 sales fell by 27% yoy to EUR 7.7m, the EBITDA contribution

significantly improved to EUR 2.5m (vs EUR -0.8m in FY 23/24), supported by the

business' seasonality.

FY 25/26, the tide looks set to turn. As reflected in the recently published

FY25/26 guidance of EUR 95-105m revenue and EUR 6-9m EBITDA, management expects

the group to return to growth following three consecutive years with a

decreasing top-line. The bottom-line should rise as a result of higher

revenue and cost cutting measures increasingly bearing fruit.

We expect moderate top-line growth of 4.8% to EUR 98.2m (eNuW) and 22%

stronger bottom-line with EUR 7.1m (eNuW) EBITDA on the basis of growing

after-sales activities, product portfolio reviews and tight cost control. In

terms of end market developments, strong growth in semiconductors, moderate

growth in consumer electronics, slight growth in automotives, mixed

performance in printing and tighter EU regulation towards packaging is

indicated by market researchers and should support the group. With tailwinds

intact and increasing revenues from ultra-pure water use cases, Disinfection

should growth by 8% yoy to EUR 28.5m (eNuW), followed by Adhesives (eNuW: +5%

yoy to EUR 35.6m) and Curing (eNuW: +2% yoy to EUR 34.1m).

Confirming BUY at a PT of EUR 15, based on DCF.

You can download the research here:

https://eqs-cockpit.com/c/fncls.ssp?u=60a0330f428b32731e6ecaee495888d9

For additional information visit our website:

https://www.nuways-ag.com/research-feed

Contact for questions:

NuWays AG - Equity Research

Web: www.nuways-ag.com

Email: research@nuways-ag.com

LinkedIn: https://www.linkedin.com/company/nuwaysag

Adresse: Mittelweg 16-17, 20148 Hamburg, Germany

++++++++++

Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss

bestimmter Börsengeschäfte.

Offenlegung möglicher Interessenkonflikte nach § 85 WpHG beim oben

analysierten Unternehmen befindet sich in der vollständigen Analyse.

++++++++++

---------------------------------------------------------------------------

The EQS Distribution Services include Regulatory Announcements,

Financial/Corporate News and Press Releases.

View original content:

https://eqs-news.com/?origin_id=14f81713-0008-11f1-8534-027f3c38b923&lang=en

---------------------------------------------------------------------------

2269304 02.02.2026 CET/CEST

°

Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer